Table 1. Summary of the clinical and laboratory characteristics of study subjects included in this study.
Patient
Number |
HIV
status |
Syphilis
stage |
Sample
type |
Pre or post-
treatment sampling # |
PCR Whole
Blood |
PCR
Serum |
RPR
titre |
TPPA
titre |
---|---|---|---|---|---|---|---|---|
1 | Positive | Secondary | Plasma | Pre | Positive | Indet. | 1/512 | >1/20480 |
2 | Negative | Primary | Plasma | Pre | Negative | Indet. | 1/4 | 1/160 |
3 | Positive | Early latent | Plasma | Pre | Negative | Positive | 1/1 | 1/1280 |
4 | Positive | Secondary | Plasma | Pre | Positive | Positive | 1/128 | 1/20480 |
5 | Positive | Secondary | Plasma | Pre | Positive | Positive | 1/128 | >1/20480 |
6 | Negative | Secondary | Plasma | Pre | Negative | Positive | 1/128 | >1/20480 |
7 | Positive | Early Latent | Plasma | Pre | Positive | Positive | 1/64 | 1/10240 |
8 | Positive | Secondary | Plasma | Pre | Positive | Indet. | 1/32 | 1/1280 |
9 | Positive | Secondary | Plasma | Pre | Positive | Positive | 1/512 | >1/20480 |
Urine | ||||||||
10 | Negative | Primary | Plasma | Pre | Positive | Indet. | 1/16 | 1/5120 |
Urine | ||||||||
11 | Positive | Secondary | Plasma | Pre | ND | Indet. | 1/128 | >1/20480 |
Urine | ||||||||
12 | Negative | Secondary | Plasma | Pre | Positive | Negative | 1/32 | >1/20480 |
13 | Positive | Secondary | Plasma | Post | ND | Indet. | 1/128 | >1/20480 |
14 | Negative | Primary | Plasma | Post | Positive | Indet. | 1/16 | 1/5120 |
Urine | ||||||||
15 | Negative | Primary | Plasma | Post | Negative | Indet. | 1/8 | 1/1280 |
16 | Positive | Secondary | Plasma | Post | Positive | Negative | 1/64 | 1/20480 |
17 | Positive | Primary | Plasma | Post | Positive | Negative | 1/64 | >1/20480 |
18 | Positive | Secondary | Plasma | Post | Negative | Negative | 1/128 | >1/20480 |
Legend: #- patients were treated with intramuscular injection with 2.4 MU Benzathine penicillin G; Indet.- indeterminate PCR result, second confirmatory PCR was not performed; ND- not done